Using advanced imaging to improve treatment safety for neuroendocrine tumors
Dosimetry-Guided 177Lu-DOTATATE Treatment Planning Using 64Cu-DOTATATE as a Surrogate
This study is testing if a new type of imaging can make Lutathera therapy safer for people with neuroendocrine tumors.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Enrollment | 10 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Wisconsin, Madison Academic / other |
| Locations | 1 site (Madison, Wisconsin) |
| Trial ID | NCT06122610 on ClinicalTrials.gov |
What this trial studies
This research aims to evaluate whether DetectnetTM PET/CT imaging can enhance the safety of Lutathera therapy for patients with neuroendocrine tumors. Participants will undergo a series of scans and visits, including a screening phase and a dosimetry phase, to assess the effectiveness of the imaging technique. The study involves both PET/CT and SPECT/CT scans to gather comprehensive data on treatment delivery. The goal is to determine if this novel imaging approach can lead to safer administration of the therapy.
Who should consider this trial
Good fit: Ideal candidates are individuals with somatostatin receptor-positive neuroendocrine tumors who are eligible for Lutathera treatment.
Not a fit: Patients who cannot tolerate lying flat for scans or have known incompatibilities with imaging techniques may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to safer treatment options for patients with neuroendocrine tumors.
How similar studies have performed: While this approach is innovative, similar imaging techniques have shown promise in enhancing treatment safety in other contexts.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Candidates for 177Lu-DOTATATE (Lutathera) treatment for somatostatin receptor-positive neuroendocrine tumor Exclusion Criteria: * Unable to lie flat during or tolerate PET/CT or SPECT/CT * Known incompatibility to CT. SPECT, or PET scans * Unlikely to comply with study procedures, restrictions and requirements and judged by the investigator that the participant is not suitable for participation in the study
Where this trial is running
Madison, Wisconsin
- University of Wisconsin - Madison — Madison, Wisconsin, United States (Recruiting)
Study contacts
- Principal investigator: Changhee Lee, MD — University of Wisconsin, Madison
- Study coordinator: Radiology Studies
- Email: Radstudy@uwhealth.org
- Phone: 608-282-8349
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.